According to statistics of the stock exchanges, pharmaceutical firm, Lupin spent the most in R&D as percentage of its net sales (8.9 per cent), Tata Motors spent the maximum in value terms (Rs 2,200 crore) in the financial year 2015.
On Wednesday, the Tata group announced it had spent Rs 17,896 crore on R&D across companies in financial year 2015, which was 2.7 per cent of the group's turnover. Analysts said while pharmaceutical companies are spending more on R&D to find new drugs to stay ahead in the game, Indian companies like Infosys are spending around 0.3 per cent of their net sales in R&D - which is not enough when compared to their global peers.
Take for example, Microsoft R&D's expenditure was $12 billion in 2015 - 13 per cent of its revenues. No wonder, Microsoft is a leader among technology companies in pursuing patents and currently has a portfolio of about 57,000 US and international patents issued and about 35,000 pending, as per its annual report of 2015. Similarly, tech giant Apple spent a staggering $8.3 billion in R&D expenditure of three per cent of its net sales in 2015.
"We are bringing innovation into our existing projects though our Zero Distance programme which has now reached 100 per cent coverage. Zero Distance is the effort we launched last year to bring innovation into every projects; to inspire teams to not just do what they are told, but to go beyond that and do something innovative," said Sikka, after announcing the FY16 results.
In FY15, Infosys spent only Rs 150 crore in R&D (see chart). Infosys's rival, TCS spent Rs 225 crore in R&D efforts in the same year and is betting big on its neural automation platform, Ignio which has won 14 multi-million dollar deals in FY16. During the post results conference with analysts, Tata Consultancy Services management highlighted that most products in the market are in robotic process automation which simply automates all tasks. The goal is to enhance Ignio into software that can practically offer all services.
India's largest private sector company, Reliance Industries spent only Rs 1,220 crore or 0.3 per cent on R&D - indicating low investments in innovations in FY15. In FY15, RIL was granted total 22 patents, in which, three for India, and 10 for USA, two for China, and one each for South Korea, Indonesia, Taiwan, Nigeria and Poland.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)